Quyen Tran

Translational research is essential for turning scientific discoveries into practical health solutions, particularly in low- and middle-income countries (LMICs). These regions bear 92% of the global disease burden but often lack the necessary resources to manage these health challenges effectively.

As the Global Health Translational Partnerships Manager at the Translational Research Office (TRO), I work to strengthen collaborations between Oxford researchers and overseas research units, such as the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Thailand and the Oxford University Clinical Research Unit (OUCRU) in Vietnam. My role focus on de-risking and accelerating the translation of early-stage research into healthcare solutions that can have real-world impacts. I hope to help improve health outcomes and advance health equity globally, where access to innovative interventions can save lives at reduced cost.

I worked at the Max-Planck Institute of Epigenetics and Immunobiology, where I researched miRNA in the regulation of post-transcriptional protein expression in diabetes. I later joined AstraZeneca, where I led global product launches, focusing on improving market access of innovative medicines for low-middle income countries. Additionally, I collaborated with GAVI to develop vaccine investment strategies that take climate change into account. Through these experiences, I had developed a unique skill set in bridging science, business, and healthcare access, with expertise across both for-profit and non-profit sectors.

I hold an MSc in International Health and Tropical Medicine and an MBA from the University of Oxford, where I was a Pershing Square Scholar.